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Amyloid precursor protein intracellular domain (AICD) is one of the potential candidates in deciphering the complexity of Alzheimer’s
disease. It plays important roles in determining cell fate and neurodegeneration through its interactions with several adaptors. The pres-
ence or absence of phosphorylation at speciﬁc sites determines the choice of partners. In this study, we identiﬁed 20 novel AICD-
interacting proteins by in vitro pull down experiments followed by 2D gel electrophoresis and MALDI-MS analysis. The identiﬁed
proteins can be grouped into diﬀerent functional classes including molecular chaperones, structural proteins, signaling and transport
molecules, adaptors, motor proteins and apoptosis determinants. Interactions of nine proteins were further validated either by colocal-
ization using confocal imaging or by co-immunoprecipitation followed by immunoblotting. The cellular functions of most of the proteins
can be correlated with AD. Hence, illustration of their interactions with AICD may shed some light on the disease pathophysiology.
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Alzheimer’s disease (AD) is a common age-related neuro-
degenerative disorder causing dementia among the elderly
[1] and is pathologically characterized by the accumulation
of amyloid plaques (called ‘senile plaques’) in the brain
parenchyma. The main components of these plaques are
the amyloid b (Ab) peptides, Ab40 and Ab42, which are
known to be neurotoxic [2]. Ab is a proteolytic peptide
fragment cleaved from the Ab precursor protein [3] by
two proteases, b- and c-secretase [4]. In addition, dense
bundles of unusual ﬁbrils of the phosphorylated protein
Tau, known as ‘neuroﬁbrillary tangles’ (NFTs), were found
in the brains of AD patients during the post-mortem exam-
ination [5]. These two molecular lesions are believed to be
the primary causative factors in AD pathogenesis and their1672-0229/$ - see front matter  2012 Beijing Institute of Genomics, Chinese A
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“tau and tangle” hypotheses, respectively [6].
The role of the C-terminal domain (i.e., C-terminal
Fragment, CTF) of amyloid precursor protein (APP)
remains relatively obscure. However, CTF has recently
been shown to be in the center of a complex protein–
protein interaction network [7]. Selective phosphorylation
of this domain is known to regulate the interaction with
the cytosolic phosphotyrosine binding (PTB) domain or
Src homology 2 (SH2) domain containing proteins
involved in cell signaling [7].
Despite this emerging molecular information, a general
understanding of the complexity of the disease is still lack-
ing, which demands an ongoing search for novel candidates
[8]. The APP intracellular domain (AICD), one of the
CTFs, is one such potential candidate that plays important
roles in biological processes including the synthesis and
metabolism of APP itself [9]. The amino acid sequence of
AICD is more conserved through evolution than that of
Ab [10]. Overexpression of AICD, without any change incademy of Sciences and Genetics Society of China. Published by Elsevier
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mice [11]. But most interestingly, AICD, through its inter-
actions with diﬀerent “adaptor” proteins inside the cell,
promotes transcriptional transactivation, Ab production,
APP traﬃcking and cellular apoptosis [9]. AICD is also
involved in modulation of gene expression, cytoskeletal
dynamics [8], cellular calcium homeostasis [12] and exerting
neurotoxicity by inducing glycogen synthase kinase-3b
expression [13]. The putative target genes for AICD include
KAI1, TAGLN, GSK3b, LRP1, X11a, mDab1 among
others [9].
AICD undergoes post-translational modiﬁcation events,
like phosphorylation of threonine (T) and tyrosine (Y) [14–
16], which inﬂuence its downstream interaction with the
adaptors. For example, phosphorylated Y682 in the con-
served motif 682YENPTY687 of APP acts as the docking
site for proteins like ShcA and Grb2 [14,17], although the
interaction of Fe65 with AICD does not require phosphor-
ylation at this site [18].
Keeping this functional involvement of AICD in mind,
our objective in this study is to ﬁnd out novel interacting
partners of AICD, especially those without any discernable
PTB domains, and try to correlate the functions of those
proteins with known AD phenotypes.
To achieve our goals, we used the tools of proteomics.
We have recently shown ‘conformational switching’ [19]
in AICD upon phosphorylation and in the present work
we targeted novel interacting partners of AICD in its
non-phosphorylated state. Several of these novel interac-
tors might be useful in understanding the protein interac-
tion network in AD pathogenesis.
Results
Identiﬁcation of AICD interactors
A bacterial expression system was used to express and pur-
ify His-AICD so as to minimize any untoward phosphory-
lation of the protein. We performed pull-down experiments
with puriﬁed His-AICD as bait and whole cell extracts
from regular N2A cells as prey to obtain AICD-interacting
partners. Six diﬀerent pull-down experiments and 2D gel
runs were performed. The protein spots which were present
in the experimental gel (pull down with AICD) but absent
in the control gel (without AICD) were considered as
potential AICD-interacting partners. On the other hand,
some protein spots were present in the control gel due to
non-speciﬁc binding of those proteins with the Ni-NTA
resin beads and those spots were not taken into consider-
ation. A total of 20 proteins were identiﬁed as potential
AICD interacting partners. Figure 1 shows a representative
2D gel for a pull-down experiment and all the protein spots
identiﬁed are marked according to the numbers given in
Table 1 (the remaining ﬁve gels are included in Figure S1).
In addition, we also performed the pull-down experi-
ment using puriﬁed mutated AICD (Y682A) as bait. As
shown in Figure S2, the 2D gel pattern was indistinguish-able from those using the puriﬁed wild type protein. MS
analysis for these spots have identiﬁed the same proteins
(data not shown). These data indicated that no PTB
protein was identiﬁed as an AICD interacting partner, as
expected. Since the bacterial expression system employed
is this study could not guarantee any site-speciﬁc phos-
phorylation (e.g., at Y and T) of the overexpressed pro-
teins, we did not recover any of the previously reported
AICD-interacting proteins, especially the PTB proteins
interacting speciﬁcally to the ‘NPTY’ motif. Hence, our
results provided an initial idea about a subset of interacting
partners of AICD which might interact with some other
parts of the domain.
The function annotation of the identiﬁed proteins was
obtained from Uniprot database. We found that these 20
proteins could be grouped into several functional classes
including molecular chaperones, structural proteins, pro-
teins related to signaling and transport, adaptor proteins,
motor proteins and apoptosis-related proteins. The identi-
ﬁed proteins and their molecular functions along with the
MASCOT score, Swissprot accession numbers and MW/
pI are listed in Table 1. The detailed MALDI-MS spectra
and images of the signiﬁcant hits based on MOWSE scores
are available on request from the authors.
Validation of the identiﬁed AICD-interacting partners
Validation for nine of the identiﬁed proteins was done by
co-immunoprecipitation (co-IP) experiments. Further-
more, heat shock 70 kDa protein 8 (HSPA8) and vimentin,
were also validated by co-localization studies using confo-
cal imaging.
The interactions of AICD with HSPA8 and vimentin
were veriﬁed by confocal microscopy as well as by
co-IP (Figure 2). AICD-GFP and HSPA8-DsRed were
co-transfected into Neuro2A (N2A) cells while cells co-
transfected with HSPA8-DsRed and empty GFP vector
served as negative control. The colocalization of AICD-
GFP with HSPA8-DsRed in N2A cells (Pearson’s coeﬃ-
cient value, R2 = 0.82) was high (Figure 2A). On the other
hand, HSPA8-DsRed did not show signiﬁcant colocaliza-
tion with empty GFP vector (R2 = 0.13) in the negative con-
trol experiment (Figure 2B). The diﬀerence in the averaged
intensity correlation quotient (ICQ) values, which indicates
the correlation of two diﬀerent signals coming from the
same pixel, obtained from these two experiments
(0.43 ± 0.06 for the experimental set and 0.07 ± 0.03 for
the control set, n = 4) was found to be signiﬁcant
(P < 0.0001) (Figure 2C). In the co-IP experiment, presence
of HSPA8-DsRed was detected in the whole cell extract as
well as in the AICD-immunoprecipitate with anti-AICD
antibody, but not in the control IgG-immunoprecipitate
in absence of anti-AICD antibody using western blot, which
veriﬁed their interaction (Figure 2D). Moreover, a recipro-
cal co-IP experiment was performed and presence of AICD-
GFP was veriﬁed in the HSPA8-DsRed immunoprecipitate
(Figure S3).
Figure 1 Representative 2D gel pattern of AICD-interacting proteins
A. Experimental gel with His-AICD as bait protein. The identiﬁed protein spots are marked as 1–20 as listed in Table 1. His-AICD is present as a patch in
the gel (marked by a circle) due to high abundance. B. Control gel without His-AICD included in pull-down experiment. The identiﬁed protein spots in
panel A are absent in the control gel. The marked spots in the control gel are present even in the absence of His-AICD and were excluded from
consideration. Both gels were stained according to the blue silver staining procedure using Coomassie G. C. Relative intensity (in arbitrary units) of each
spot with respect to control from six diﬀerent pull-down experiments. The protein names corresponding to the spot numbers are also given. The same
molecular weight markers and pH 3–10 IPG strips were used in all the experiments.
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and vimentin was also carried out by confocal imaging as
well as by co-IP. Signiﬁcant colocalization was revealed
between AICD-GFP and vimentin-DsRed (Figure 2E,
R2 = 0.91) but not in case of vimentin-DsRed and empty
GFP vector (Figure 2F, R2 = 0.36). Both AICD and
vimentin were observed to be co-localized in cytosol as well
as in the nucleus, which is consistent with the cellular dis-
tribution reported elsewhere [20]. A signiﬁcant diﬀerence
(n = 4; P = 0.0003) in the averaged ICQ values between
experimental (0.40 ± 0.09) and control (0.08 ± 0.06) sets
of experiments was apparent for vimentin (Figure 2G). In
addition, our co-IP experiments showed that vimentin-
DsRed was detected in the whole cell extract and in the
AICD-immunoprecipitate but absent in the control IgG-
immunoprecipitate (Figure 2H).
Representative images of the ICQ analysis for each of
the confocal experiments are included in Figure S4 (A–D).Validation of interaction with AICD for seven other
proteins namely, NUDC, notch2NL, cystatin S precursor,
dynein, ﬁbrinogen c, laminin c and CASP8AP2, were done
by co-IP experiments followed by western blotting
(Figure 3). Presence of each of the above-mentioned
proteins in western blot clearly veriﬁed the interactions
and validated our results.
Discussion
AICD is known to have two non-overlapping repertoires of
interactors depending on its state of phosphorylation [9]. In
their study with phosphorylated forms of AICD, Tamayev
et al. have shown that mutually exclusive phosphorylation
at Y682 or T668 changed its interactome pattern [21]. They
have also reported that AICD can bind to some proteins
like NUMB in a phosphorylation-independent manner
[22]. For an intrinsically unstructured protein (IUP) like
Table 1 List of potential AICD-interacting proteins identiﬁed by MALDI-MS
Spot No. Protein name Swiss-Prot accession
no.
MW (kDa)/
pI
MASCOT
score
Molecular function
1 HSPA8 P11142 71.1/5.37 247 Molecular chaperone
2 NEXN protein
(fragment)
Q7Z2X0 26.6/8.97 93 Regulation of cell migration
3 NPD011/NUDC Q9Y266 38.0/5.71 75 Neurogenesis & neuronal migration
4 Notch2NL Q7Z3S9 26.0/5.22 122 Involved in notch signaling pathway
5 Fibrillin-2 precursor P35556 314.8/4.76 142 Structural components of extracellular calcium-
binding microﬁbril
6 CASP8AP2 (fragment) Q5T791 220.3/6.08 91 Involved in apoptotic signaling
7 Cystatin S precursor P01036 16.2/4.95 106 Strongly inhibits papain and ﬁcin
8 APOA4 P06727 22.0/9.34 201 May have a role in VLDL secretion and catabolism
9 GRP78/HSPA5 P11021 72.1/5.03 226 Facilitates multimeric protein complex assembly inside
ER
10 Selenium-binding
protein
Q13228 52.3/6.13 136 May be involved in intra-Golgi protein transport
11 Galectin-1 P09382 14.6/5.33 83 May regulate apoptosis, cell proliferation and
diﬀerentiation
12 Vimentin P08670 53.5/5.06 139 Class III intermediate ﬁlaments
13 HSP90b P14625 62.6/6.4 198 Molecular chaperone, with ATPase activity
14 Kelch-like protein 6 Q8WZ60 69.1/5.83 53 B-lymphocyte antigen receptor signaling
15 Fibrinogen c P02679 51.0/5.68 100 Monomers that polymerize into ﬁbrin
16 Dynein, axonemal Q0VDD8 76.0/6.01 70 Microtubule-associated motor protein
17 Lamin B2 Q03252 67.6/5.29 55 Component of nuclear lamina
18 SH3TC1 Q8TE82 146.8/5.85 17 Exact function is not known
19 Laminin c Q9Y6N6 171.9/6.29 27 Attachment, migration and organization of cells into
tissues
20 GAB2 Q9UQC2 74.4/8.54 66 Adaptor for transmitting various signals
Note:Molecular functions for the identiﬁed proteins were obtained from the Uniprot database. MW, molecular weight; SH3TC1, SH3 domain and tetra-
tricopeptide repeats-containing protein 1.
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at Y682 is now established, ensuring diﬀerent binding
interfaces for two diﬀerent genres of adaptors. The range
of alteration of binding for non-PTB binding partners,
when Y682 is mutated, needs to be checked spectroscopi-
cally in future. In a real scenario there should be a balance
of phosphorylated to non-phosphorylated forms of AICD
within the cell. In our study, we have emphasized the later
part of the interactome and, as expected, have not found
any of the known interactors of AICD which have been
reported to be PTB domain-containing proteins requiring
phosphorylation of AICD at either Y682 or T668. To
ensure that our targets were interacting partners of AICD
independent of any phosphorylation event, AICD was
expressed in a bacterial expression system where site-
speciﬁc phosphorylation could be ruled out, and further
possibility of any enzymatic modiﬁcation at speciﬁc posi-
tion of resin-bound AICD should be minimal. The cholin-
ergic hypothesis behind hippocampal vulnerability in
Alzheimer’s disease has been supported very recently [23].
Keeping this in mind, we have chosen the Neuro2A cell line
where the signaling was choline driven, expecting direct
lines of newly identiﬁed interacting partners and AD-like
condition. Since the interactions of AICD with other pro-
teins within the cell might have a cumulative inﬂuence on
the diseased condition, our goal was to identify as many
numbers of interacting partners of AICD and to assess
the functional implications of these interactions.Of the 20 interactors that were deciphered (Table 1),
seven proteins namely laminin [24], HSPA8, HSP90b,
GRP78/HSPA5 [25,26], GAB2 allele [27], vimentin [28],
and cystatin C [29] were already described in the litera-
ture to be involved in the AD process. The fact that
AICD interacted with these proteins gave a new dimen-
sion to it. Several others like selenium-binding protein,
galectin-1, kelch-like protein 6 and SH3 domain and
tetra-tricopeptide repeats-containing protein have never
been reported in connection to AD and any guess
regarding their functional signiﬁcance would be
premature.
A neurodegenerative disease like AD is caused by the
gain of toxic function of misfolded proteins/peptides (Ab
and Tau) and the shift of balance towards misfolded pro-
teins could be ascribed to aberrant chaperone activities
[25]. Delineation of interactions of AICD with molecular
chaperones may possibly illustrate its involvement in dis-
ease pathogenesis. A number of studies have recently been
reported explaining the possible role of molecular chaper-
ones such as the heat shock proteins (HSPs) in AD
[26,30]. These interactions might disrupt the protein fold-
ing machinery and increase the proportion of misfolded
proteins in the cytosol. For example, cytosolic HSP70
and HSP90 were implicated in inhibiting early amyloid
aggregates [31] and the equilibrium of the reaction could
be disrupted due to their involvement in the interaction
with AICD.
Figure 2 Validation of interaction of AICD with HSPA8 and vimentin
A. Colocalization of AICD-GFP and HSPA8-DsRed in N2A cells. Magniﬁcation bars are included. Pearson’s correlation coeﬃcient (R2) for
colocalization is 0.82. B. Colocalization pattern of empty GFP vector with HSPA8-DsRed. No signiﬁcant colocalization was obtained. Pearson’s
correlation coeﬃcient (R2) for colocalization is 0.13. C. Bar graph showing the signiﬁcant diﬀerence in normalized ICQ for colocalization between AICD-
GFP and HSPA8-DsRed with that between empty GFP vector and HSPA8-DsRed (n = 4, P < 0.0001).D. Western blots showing co-IP of HSPA8-DsRed
with AICD-GFP. Bound proteins were immunoprecipitated with anti-AICD antibody and blotted with anti-DsRed antibody. E. Colocalization of AICD-
GFP and vimentin-DsRed in N2A cells. Pearson’s correlation coeﬃcient (R2) for colocalization is 0.91. F. Colocalization pattern of empty GFP vector
with Vimentin-DsRed. No signiﬁcant colocalization was obtained. Pearson’s correlation coeﬃcient (R2) is 0.36. G. Bar graph showing the signiﬁcant
diﬀerence in ICQ for colocalization between AICD-GFP and Vimentin-DsRed to that between empty GFP vector and Vimentin-DsRed (n = 4,
P = 0.0003). H. Western blots showing co-IP of vimentin-DsRed with AICD-GFP. Bound proteins were immunoprecipitated with anti-AICD antibody
and blotted with anti-DsRed antibody.
Figure 3 Validation of interaction of AICD with seven other proteins
Interactions of seven other potential interacting partners of AICD namely
NUDC, CASP8AP2, dynein, cystatin S precursor, ﬁbrinogen c, notch2NL
and laminin c were validated by co-IP followed by western blot. Western
blot of co-IPwith each protein shows presence of target protein in whole cell
extract (input) as well as in AICD-immunoprecipitate sample (AICD-IP)
and absence in the control immunoprecipitate sample (IgG-IP). A repre-
sentative blot reprobed for AICD-GFP was shown in the bottom panel.
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required for apoptotic signaling within the cell and for
induction of neuronal apoptosis by b-amyloid, especiallyby caspase8 [32]. The interaction of AICD with caspase 8
associated protein 2 (CASP8AP2) fragment, therefore,
would indicate an indirect association of AICD in neuronal
apoptosis. AICD was reported to be involved in induction
of neuron-speciﬁc apoptosis [10], and hence, as a compo-
nent of the caspase complex, it could possibly enhance
the apoptotic signal by caspase 8.
The protein cystatin C, on the other hand, was reported
to inhibit Ab deposition in the AD mouse model [29]. Both
cystatin C and cystatin S are members of the cystatin
superfamily [33], the interaction of AICD with cystatin S
precursor, as we have shown, might show a distant line
between the proteolytic generation of these toxic fragments
and their subsequent deposition.
Apart from an aggregation issue, loss of structural integ-
rity is a deleterious feature of AD [34]. The structural pro-
teins ﬁbrillin-2 precursor, ﬁbrinogen c and vimentin, which
were identiﬁed as AICD interactors in this study, should
have important roles in cellular disintegration. Fibrinogen
c-A chain precursor was previously reported as a candidate
CSF biomarker for AD [35], which is in agreement with
our result. The interaction of protein ﬁbrillin2, a structural
component of extracellular Ca2+-binding microﬁbril, with
AICD could relate AICD to cellular calcium homeostasis.
In addition, we also revealed two important traﬃc compo-
nents as AICD interactors. These include dynein, which is
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transport, mitosis and ciliary and ﬂagellar beating [36], and
NudC, which is a dynein-associated nuclear movement
protein involved in mitosis and cytokinesis [37]. In an
AD-like cellular model, AICD is transported via endocytic
vesicles in association with growth factor receptor-bound
protein 2 (Grb2) in the cytosol [38]. Grb2 is known to inter-
act with dynein via its N-terminal SH2 domain [39]. As
AICD is also transported into the nucleus and inﬂuences
cytoskeletal dynamics [8], its interaction with a dynein
complex therefore is signiﬁcant. Additionally, NUDC
plays roles in neurogenesis and neuronal migration and
AICD may aﬀect these processes by interacting with
NUDC. Two other novel interactors including LaminB2,
a component of the inner nuclear membrane and the
nuclear envelope framework [40], and NEXN, a ﬁlamen-
tous actin-binding protein involved in cell migration [41],
imply the possibility of AICD’s involvement in cell motility
and division. Together with our observations regarding the
dynein complex, these data suggests the involvement of
AICD in the loss of cellular integrity, which is a novel
aspect that should be explored further.
In addition to cellular disintegration, generation of
pathologically important proteolytic fragments of APP
would destabilize cellular homeostasis and dynamics.
Major disruptions in lipogenic pathways in AD are well
established. Apolipoprotein A-IV (ApoA4), a cholesterol-
binding lipoprotein, is reported to be associated with AD
pathology [42] and its interaction with AICD signiﬁes
similar disruption possibilities. Another ﬁnding, laminin,
has been implicated in a wide spectrum of biological pro-
cesses including cell adhesion, diﬀerentiation, migration,
signaling, neurite outgrowth and metastasis [43]. Interest-
ingly, laminin was reported to exert anti-amyloidogenic
eﬀects in rat primary hippocampal neurons, by interacting
with Ab and inhibiting amyloid ﬁbril formation [24]. The
interaction of AICD with laminin c may have far-reaching
eﬀects on the disease process.
Notch, which is well known in cell proliferation, is pro-
cessed similarly to APP and its intracellular domain
(NICD) goes directly into the nucleus [44]. NICD compet-
itively inhibits AICD-Tip60-Fe65 complex to aﬀect neuro-
nal cell death [45]. Our observation of notch 2 N-terminal
like (Notch2NL) as an interacting partner of AICD pre-
cludes the possibility of a similar inhibitory eﬀect on intra-
cellular AICD dynamics.
There are reports that Grb2-associated binding protein 2
(GAB2) inﬂuences AD neuropathology in ApoEe4 carrier
individuals [27] and is an AD susceptibility gene [46].
Understandably, it is an important protein in respect of
AD pathogenesis which we have obtained as an AICD-
interacting partner.
Despite the lack of direct biophysical examinations
like ﬂuorescence resonance energy transfer (FRET) or
isothermal titration calorimetry (ITC) to support interac-
tions of each pair, the list of identiﬁed novel interactors
of AICD presented in this work enriches the repertoireof functions that a natively-unfolded protein could
achieve post generation. Starting from early survival
events like prevention of protein aggregates, altered cellu-
lar motility, vesicle traﬃcking to cell death, via cytoskel-
etal restructuring, AICD holds promise as an important
modulator downstream of intramembrane proteolysis.
Despite initial scepticism regarding the stability of this
CTF [3,47], recent results support its role in creating
AD-like phenotypes in mouse model [11]. It is possible
that the initial scepticism regarding the stability of AICD
came out of experiments which followed non-amyloido-
genic processing of APP on the plasma membrane.
Recent reports, on the contrary, focussed on amyloido-
genic lysosome membrane centric events resulting in the
generation of a relatively stable AICD having down-
stream cellular consequences. Expanding the AICD inter-
actome and delineating its newer functionalities would
help resolve this apparent ambiguity.
Materials and methods
Molecular cloning of AICD
The nucleotide sequence coding the human AICD frag-
ment (NCBI Accession number NP_000475.1; amino acid
724-770 of the whole APP protein) was cloned into the bac-
terial expression vector pET28a+ and also into mammalian
expression vector pEGFP (C-terminal fusion) as described
earlier [19,38]. The mutant His-AICD (Y682A) in
pET28a+ was generated using site-directed mutagenesis.
HSPA8-DsRed-C1 and Vimentin-DsRed-C1 constructs
were obtained as generous gifts from Prof. Nitai P. Bhatta-
charyya of Saha Institute of Nuclear Physics, Kolkata. All
constructs were conﬁrmed by sequencing.
Expression and puriﬁcation of His-AICD
The plasmid containing wild type AICD or mutant AICD
(Y682A) in pET28a+ was transformed using the CaCl2
transformation method into the Escherichia coli BL21-
DE3 for protein expression. As described earlier, His-
tagged proteins were puriﬁed using Ni-NTA resin column
[19]. The concentration of the His-AICD proteins (wild
type and mutant) was measured using the Bradford protein
assay. This puriﬁed AICD and the mutant proteins were
used as the “bait” protein in the pull-down assay.
Cell culture and extraction of Neuro2A proteins
N2A cells were grown at 37 C in a humidiﬁed 5% CO2
incubator in DMEM media supplemented with 10% fetal
bovine serum (FBS). For confocal imaging or co-IP
experiments, log phase-N2A cells were transfected with
constructs of interest using Lipofectamine Reagent (Invit-
rogen, USA) (ratio 1:3 for DNA:lipofectamine) as
instructed by the manufacturer to obtain transient overex-
pression of the target proteins.
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with cold 1  phosphate buﬀered saline (PBS) on ice. The
cell pellets were resuspended in lysis buﬀer (50 mM Tris–
HCl pH 7.5, 1 mM EDTA, 150 mM NaCl, 2 mM PMSF,
0.5% NP-40 and 1  protease inhibitor cocktail, Pierce)
and rapid freezing and thawing was carried out to rupture
the cell walls. After centrifugation at 13,000 rpm for 15 min
at 4 C, the supernatant containing the whole cell proteins
was collected and used as the “prey” protein in the pull-
down assay or as input for the co-IP experiments.
Pull-down experiment
Pull-down experiments were performed using the Pro-
Founde Pull-Down PolyHis Protein: Protein Interaction
Kit (Thermo Scientiﬁc, Prod No. 21277). Puriﬁed
His-AICD was used as bait and non-transfected N2A cell
extract was used as prey in this experiment. Puriﬁed
His-AICD was bound to the Ni-NTA based resin column
for 4 h. After washing thrice with lysis buﬀer to remove
unbound AICD, AICD-bound resin was incubated
overnight with N2A whole cell extract. For 200 lg of bait
protein, 800 lg of prey protein was used. This experiment
was repeated several times to obtain a reproducible pattern
of spots on 2D gel. Every time a control experiment was
done by following the same pull-down protocol in absence
of bait protein (His-AICD). After discarding the ﬂow-
through and subsequent washing with lysis buﬀer, the
interaction complex as well as the control fraction was
eluted using 300 mM imidazole. In addition, we also
performed the same pull-down experiment using mutated
His-AICD protein as bait where a point mutation,
Y682A, was introduced in the ‘NPTY’ motif of AICD.
Two-dimensional gel electrophoresis
The eluted protein complex from the pull-down experiment
was acetone precipitated and the proteins were pelleted by
centrifugation at 12,000 rpm for 10 min. The protein pellet
was dissolved in 2D rehydration buﬀer (8 M urea, 4%
CHAPS, 2% DTT, 2% ampholyte pH 3–10 and 30 mM
Tris–HCl pH 8.5) and IPG strips were rehydrated with the
experimental sample and the control. After the ﬁrst dimen-
sion (isoelectric focusing), IPG strips were equilibrated for
15 min in reducing equilibration buﬀer (50 mM Tris–HCl
pH 8.8, 6 M urea, 30% glycerol, 2% SDS and 50 mM
DTT) followed by 15 min in alkylating equilibration buﬀer
containing 2.5% (w/v) iodoacetamide instead of DTT.
After gel electrophoresis, the 2D gels were stained with
coomassie brilliant blue or silver or blue silver staining
[48]. Diﬀerent staining procedures were used in diﬀerent
experiments depending on the amount of protein present
in the eluted fraction after pull-down. After staining, the
protein spots were compared between the experimental
and the control gel. The proteins spots which were present
in the experimental gel but absent in the control gel were
considered to be potential AICD-interacting partners. Wecompared the relative intensity (in arbitrary units) of each
unique spot in the experimental gel to that in the control
gel by selecting the same spot volume. The ratios of inten-
sity for each spot obtained in at least ﬁve among the total
six diﬀerent pull-down experiments were calculated and the
relative intensities were plotted (Figure 1C). For some of
the proteins (e.g., spot 9), the corresponding spot was
detected in all the six gels, which were all included in the
plot. The spots were excised from the gel and processed
for the subsequent MALDI-MS identiﬁcation.
MALDI-MS analysis and protein identiﬁcation
The excised spots were destained and then tryptic digestion
was performed overnight In-Gel tryptic Digestion Kit
(Pierce, USA). The digestion mixture was lyophilized in a
Heto vacuum centrifuge (Thermo) and resuspended in
50% Acetonitrile (ACN) and 0.1% Triﬂuoroacetic acid
(TFA) solution. The dissolved samples were mixed 1:1
(v/v) with a-Cyano-4-hydroxycinnamic acid (CHCA)
matrix and spotted on the MALDI plate and air dried.
MALDI analyses were performed with a 4700 Proteomic
Analyzer MALDI-TOF/TOF (Applied Biosystems) for
identiﬁcation of the protein spots. Peptide mass ﬁnger-
printing data was acquired in positive MS reﬂector mode
using a ﬁxed laser intensity of 5500 with 2000–3000 laser
spots in the range 800–4000 Da, signal to noise ratio 10
and mass exclusion tolerance of 150 ppm. Internal calibra-
tion was done in the instrument with minimum signal to
noise of 20 and mass tolerance of ±300 ppm taking mono-
isotopic peaks only. The isolation of peptides of interest
was carried out at a relative resolution of 50 (full width
at half maximum) and data from 3000 to 5000 laser shots
were collected. Spectral data was analyzed with GPS
Explorere version 3.6 (Applied Biosystems). Peptide iden-
tiﬁcation was based on the MASCOT database scoring
algorithm from Swiss-Prot and NCBI protein databases
using search settings of: single missed tryptic cut, ﬁxed
carbamidomethylation, variable methionine oxidation
and N-terminal acetylation and 150 ppm mass accuracy.
Autolytic tryptic peaks were excluded in the MASCOT
search parameter and P < 0.05 was considered signiﬁcant
during identiﬁcation. Since we had taken a gel-based
proteomics approach, we could identify speciﬁc proteins
from a particular spot according to the molecular weight
and pI from the protein list given by MASCOT server.
Confocal microscopy
N2A cells were transfected with AICD-GFP in combination
with HSPA8-DsRed or vimentin-DsRed. A vector control
was set by overexpressing empty GFP vector with either of
HSPA8-DsRed and vimentin-DsRed in N2A cells to nullify
the contribution of GFP in the colocalization studies.
An LSM 510 META confocal laser scanning microscope
(Carl Zeiss, Jena, Germany) was used for the imaging stud-
ies and images were captured with either 40 or 63 objec-
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square of the Pearson correlation coeﬃcient value (Rp),
where this squared value, R2, was deﬁned as the percentage
of variance of the ﬁrst channel which could be explained by
or which was dependent on the variance of the second
channel. Only when this percentage of overlap between
the two channels exceeded 0.50, did we consider those to
have signiﬁcant colocalization. As Pearson’s coeﬃcient
might not be sensitive to the intensity of the background,
we performed intensity correlation analysis (ICA) as
described by Li et al. [49] and obtained the intensity corre-
lation quotient (ICQ) to test whether the color overlap was
dependent (0 < ICQ 6 0.5) or random (ICQ0) using Ima-
geJ open-source software (http://www.rsb.info.nih.gov/ij).
No thresholding was applied for the ICQ analyses. For sta-
tistical analysis, unpaired t-test was performed to compare
the normalized ICQ values of the negative controls and
experimental sets for both HSPA8 and vimentin using the
online software GraphPad QuickCalcs.
Co-immunoprecipitation
For the interaction validation of HSPA8 or vimentin with
AICD, N2A cells were transiently co-transfected with
AICD-GFP and either of vimentin-DsRed or HSPA8-
DsRed constructs. After harvesting, soluble cell extracts
were prepared similarly as described previously (see “Cell
culture and extraction of Neuro2A proteins”) from these
co-transfected N2A cells. Sixty micrograms of the whole
cell extract was used as input in each experiment and
200 lg extract was incubated overnight with anti-mouse
AICD antibody (monoclonal, Chemicon, Cat. No.
mab343) and Protein A/G beads. After SDS–PAGE and
western transfer, presence of particular protein in the
AICD interaction complex was revealed by immunoblot-
ting with anti-DsRed primary antibody (Clontech, rabbit
polyclonal, Cat. No. 632496). In addition, a reciprocal
co-immunoprecipitation was also performed for interac-
tion between HSPA8 and AICD. Whole cell extract from
N2A cells expressing HSPA8-DsRed and AICD-GFP
was incubated with anti-DsRed antibody and the complex
was blotted with anti-GFP antibody (Clontech, mouse
monoclonal, Cat. No. 632375).
For validating the interaction of AICD with other 7 pro-
teins, N2A cells were transfected with AICD-GFP and co-
IP was performed using anti-AICD antibody to pull the
AICD-interaction complex and the immunoblots were
probed with antibody against the endogenous protein of
interest (AICD-interacting protein). A negative control
was set for each of the interaction validations using mouse
anti-IgG primary antibody instead of anti-AICD antibody
to rule out non speciﬁc binding of the proteins with the A/
G beads. The immunoblot was reprobed with anti-AICD
antibody to verify the presence of AICD in the complex.
Mouse monoclonal antibodies to dynein (Cat. No.
ab23905), notch2NL (Cat. No. ab57806) and NUDC
(Cat. No. ab56999) were purchased from Abcam. Antibod-ies to cystatin S (mouse monoclonal, Cat. No. sc133496),
ﬁbrinogen c (mouse monoclonal, Cat. No. sc133157),
laminin c 3 (rabbit polyclonal, Cat. No. sc25719) and
CASP8AP2 (rabbit polyclonal, Cat. No. sc9088) were pur-
chased from Santa Cruz Biotechnology.
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